[go: up one dir, main page]

ATE147634T1 - Produkte zur behandlung des endotoxin -schocks bei einem säugetier - Google Patents

Produkte zur behandlung des endotoxin -schocks bei einem säugetier

Info

Publication number
ATE147634T1
ATE147634T1 AT89121661T AT89121661T ATE147634T1 AT E147634 T1 ATE147634 T1 AT E147634T1 AT 89121661 T AT89121661 T AT 89121661T AT 89121661 T AT89121661 T AT 89121661T AT E147634 T1 ATE147634 T1 AT E147634T1
Authority
AT
Austria
Prior art keywords
mammal
products
endotoxin shock
effective amount
therapeutically effective
Prior art date
Application number
AT89121661T
Other languages
English (en)
Inventor
Allan Wissner
Suresh S Kerwar
Constance Kohler
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ATE147634T1 publication Critical patent/ATE147634T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Thermistors And Varistors (AREA)
  • Measurement Of Force In General (AREA)
  • Percussive Tools And Related Accessories (AREA)
  • Disintegrating Or Milling (AREA)
  • Surgical Instruments (AREA)
AT89121661T 1988-12-19 1989-11-23 Produkte zur behandlung des endotoxin -schocks bei einem säugetier ATE147634T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28620188A 1988-12-19 1988-12-19

Publications (1)

Publication Number Publication Date
ATE147634T1 true ATE147634T1 (de) 1997-02-15

Family

ID=23097534

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89121661T ATE147634T1 (de) 1988-12-19 1989-11-23 Produkte zur behandlung des endotoxin -schocks bei einem säugetier

Country Status (18)

Country Link
US (1) US5124147A (de)
EP (1) EP0374510B1 (de)
JP (1) JP2931344B2 (de)
KR (1) KR0148680B1 (de)
AT (1) ATE147634T1 (de)
AU (1) AU624457B2 (de)
CA (1) CA2005670A1 (de)
DE (1) DE68927671T2 (de)
DK (1) DK641889A (de)
ES (1) ES2096553T3 (de)
FI (1) FI896046A7 (de)
GR (1) GR3022969T3 (de)
IL (1) IL92471A (de)
NZ (1) NZ231725A (de)
PH (1) PH31376A (de)
PT (1) PT92596B (de)
SG (1) SG43205A1 (de)
ZA (1) ZA899685B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5147864A (en) * 1988-12-19 1992-09-15 American Cyanamid Company Bis-arylphosphate ester antagonists of platelet activating factor
US5231091A (en) * 1988-12-19 1993-07-27 American Cyanamid Company Bis-arylphosphate ester antagonists of platelet activating factor
US4983592A (en) * 1988-12-19 1991-01-08 American Cyanamid Co. Bis-arylphosphate ester antagonists of platelet activating factor
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
EP0546076B1 (de) * 1990-08-31 1998-05-20 Boehringer Ingelheim Pharmaceuticals Inc. Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
WO1993011793A1 (en) * 1991-12-17 1993-06-24 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
JPH09507578A (ja) * 1994-01-14 1997-07-29 ジェネンテク，インコーポレイテッド インスリン受容体チロシンキナーゼインヒビターに対するアンタゴニスト
CA2185162A1 (en) 1994-03-07 1995-09-14 Robert F. Halenback (Deceased) Compositions for the inhibition of tnf formation and uses thereof
US5939269A (en) * 1994-12-28 1999-08-17 The Regents Of The University Of California Antagonists to insulin receptor tyrosine kinase inhibitor
DE69622157T2 (de) * 1995-01-23 2003-03-13 Xenotech Inc., Fremont Zusammensetzung zur verhinderung von osteolyse und metastasen
US20020025316A1 (en) * 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
GB2304342A (en) * 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
CA2364983A1 (en) * 2000-12-13 2002-06-13 John R. Coleman Nucleic acid molecules and polypeptides for catabolism of abscisic acid
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
EP2361933A3 (de) 2005-01-26 2012-05-02 Amgen Fremont Inc. Antikörper gegen Interleukin-1 Beta
WO2006125229A2 (en) 2005-05-16 2006-11-23 Abbott Biotechnology Ltd. Use of tnf inhibitor for treatment of erosive polyarthritis
TWI392684B (zh) 2006-04-05 2013-04-11 亞培生物科技公司 抗體之純化
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20100329983A1 (en) 2009-06-26 2010-12-30 Soricimed Biopharma Inc. Compounds and methods for the detection of trpv-6 cancers and drug delivery
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (de) 2015-04-10 2016-10-12 Ares Trading S.A. Induktionsdosierschema zur behandlung von krankheiten die von tnf alpha verursacht sind
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148879A (en) * 1977-12-23 1979-04-10 Nelson Research & Development Company Inhibition of platelet aggregation with selected phosphonic and phosphinic acid esters

Also Published As

Publication number Publication date
ZA899685B (en) 1990-09-26
JPH02212435A (ja) 1990-08-23
DE68927671D1 (de) 1997-02-27
DK641889D0 (da) 1989-12-18
SG43205A1 (en) 1997-10-17
KR0148680B1 (ko) 1998-08-17
PH31376A (en) 1998-10-29
CA2005670A1 (en) 1990-06-19
DK641889A (da) 1990-06-20
KR900009097A (ko) 1990-07-02
AU4688589A (en) 1990-06-21
DE68927671T2 (de) 1997-05-07
GR3022969T3 (en) 1997-06-30
AU624457B2 (en) 1992-06-11
EP0374510A1 (de) 1990-06-27
EP0374510B1 (de) 1997-01-15
NZ231725A (en) 1992-12-23
IL92471A0 (en) 1990-08-31
PT92596B (pt) 1996-06-28
IL92471A (en) 1995-06-29
JP2931344B2 (ja) 1999-08-09
US5124147A (en) 1992-06-23
ES2096553T3 (es) 1997-03-16
PT92596A (pt) 1990-06-29
FI896046A0 (fi) 1989-12-18
FI896046A7 (fi) 1990-06-20

Similar Documents

Publication Publication Date Title
ATE147634T1 (de) Produkte zur behandlung des endotoxin -schocks bei einem säugetier
ATE172880T1 (de) Verwendung von monoklonalen anti-tnf-antikörpern für die behandlung von bakteriellen meningitiden
DE68920693D1 (de) Gefriergetrocknete Zusammensetzung, die ein mit Meerrettichperoxydase markiertes Fab'-Fragment eines gegen menschliches Beta-Interferon gerichteten Antikörpers und Trehalose enthält; EIA Kit, der diese Zusammensetzung enthält.
FI954347L (fi) Monoklonaaliset vasta-ainekoostumukset ja monoklonaalisia vasta-aineita tuottavat hybridomat
DE69319662D1 (de) Monoklonale Antikörper gegen GP130-Protein
DK0492448T3 (da) Monoklonale antistoffer mod human tumor-nekrotiserende faktor alfa
IT8320550A0 (it) Procedimento di purificazione peraffinita' in cui si impiegano anticorpi monoclonali.
DK149990A (da) Familie af modificerede antistoffer med hoej affinitet til cancerbehandling
DE3482905D1 (de) Monoklonale antikoerper gegen lungenkrebs des "nicht-kleine-zellen"-typs.
ATE93144T1 (de) Methode zur verminderung der immunglobulin-ereaktion.
DE69024279D1 (de) Cytokine
DE3580382D1 (de) Monoklonale antikoerper gegen alpha-2 interferon und hybridomas, die solche antikoerper produzieren.
IT8921517A0 (it) Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
ATE98872T1 (de) Antagonist fuer interleukin-5 zur verhuetung oder verminderung von eosinophilie.
FI922551A0 (fi) Foerfarande foer skoetsel av septisk chock.
FI911311A7 (fi) Gramnegatiivisten bakteerien endotoksiinin vaikutuksen ehkäiseviä mono klonaalisia vasta-aineita
DK717888D0 (da) Monoklonale antistoffer
DK592086A (da) Humant conglutinin
IT1163911B (it) Resina per lenti di elevata rifrattivita' e lenti prodotte con la resina stessa
IT1239065B (it) Anticorpo monoclonale che inibisce l'azione biologica del fattore piastrinico 4
FI895829A7 (fi) Ihmisen monoklonaaliset vasta-aineet rabiesvirusta vastaan
FI924278A0 (fi) Bcrf1 antagonister foer skoetsel av epstein-barr-virusinfektioner.
FI925638A7 (fi) Kasvainten yhteydessä esiintyvää antigeenia vastaan suunnattu monoklonaalinen vasta-aine 88BV59
CS512290A3 (en) Mouse hybridoma ifna1-118 producing monoclonal antibody binding the human interferon alpha 1
CS511090A3 (en) Mouse hybridoma ifna2-n10 producing monoclonal antibody binding the human interferon alpha 2

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee